2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1694

Does Treat to Target or Achieving Remission Improve Radiographic Outcome in Psa?
Abstract Number: 1036

Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis
Abstract Number: 2035

Dosage Contribution of a Non-Classical HLA Gene, HLA-Doa, to the Risk of Rheumatoid Arthritis
Abstract Number: 3013

Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission – 1-Year Results of a Guideline-Directed Longitudinal Cohort Study
Abstract Number: 1644

Dose Selection of Filgotinib, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 3 Studies: Exposure-DAS28 and ACR Modeling Approach
Abstract Number: 2359

Dose-Related Risks of Cardiovascular, Gastrointestinal, and Renal Adverse Events Associated with Meloxicam Among Patients with Osteoarthritis: An Observational Study Using US Claims Data
Abstract Number: 2480

Dose-Related Short Term Clinical Response to Initial Treatment with Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients – a Meta-Regression Analysis
Abstract Number: 1597

Dose-Response Modeling Is a Useful Tool to Determine Doses for Phase 3: Experience from Olokizumab
Abstract Number: 1754

Double-Negative T (DNT) Cell over-Expressing PD-1 and Helios Is Responsible for Lupus Tissue Injury in Systemic Lupus Erythematosus (SLE): Direct Proof That Increased Interferon Alpha (IFNα) Expression Is Sufficient to Induce SLE in Ifnα-Transgenic Mice
Abstract Number: 808

Down-Regulation of microRNA-126 in Scleroderma Microvascular Endothelial Cells (MVECs) Is Associated with Impaired Responses to Vascular Endothelial Growth Factor (VEGF) and Defective Angiogenesis
Abstract Number: 1750

Down-Regulation of microRNA-200a-3p, Targeting C-Terminal Binding Protein-2 (CtBP2), Is Involved in Hypoproduction of IL-2 in SLE-Derived T Cells
Abstract Number: 784

Drivers of the SLE Responder Index (SRI) Endpoint in Clinical Trials of SLE
Abstract Number: 11

Drug Prescribing Trends in Adults with Rheumatoid Arthritis: A Population-Based Comparative Study from 2005-2014
Abstract Number: 2527

Drug Retention of Biologics in Rheumatoid Arthritis Patients: The Role of Baseline Characteristics and Impact of Time-Varying Factors
Abstract Number: 327

Drug Retention Rate of Oral Bisphosphonate in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].